CLIPAD

COMPARE Pilot RCT 2-Year Results Show Similar Patency for Low-Dose and High-Dose Drug-Coated Balloons

01/24/2020

Michael R. Jaff, DO, Vice President of Clinical Affairs, Innovation, Technology and Peripheral Interventions at Boston Scientific, presented results from the COMPARE Pilot randomized clinical trial on Friday morning at the International...

Michael R. Jaff, DO, Vice...

01/24/2020

Vascular Disease Management

Critique of New Meta-Analysis of Paclitaxel Highlights Issues in Study Construction

01/23/2020

The study design of a recently published meta-analysis by Katasanos and colleagues is flawed, according to a critique presented by William Gray, MD, at the International Symposium on Endovascular Therapy (ISET).

The study design of a recently...

01/23/2020

Vascular Disease Management

IN.PACT DEEP Global Shows Real-World Effectiveness, Safety

01/23/2020

Hollywood, FL (January 23, 2020)- Results of the IN.PACT DEEP Global study show durable effectiveness and safety of the IN.PACT Admiral drug-coated balloon (DCB) (Medtronic) through 4 years, according to data presented by Gunnar Tepe, MD, at...

Hollywood, FL (January 23,...

01/23/2020

Vascular Disease Management

01/23/2020

Hollywood, FL (January 23, 2020) – In the first and only head-to-head comparison of two paclitaxel-eluting stents used in peripheral intervention, no difference was seen for the primary endpoint of primary patency at 24 months. Clinical...

Hollywood, FL (January 23, 2020)...

01/23/2020

Vascular Disease Management

Meeting Exclusives

SAVER: Stellarex Data in Complex Patients Notch Another Win for DCB

01/23/2020

The Stellarex drug-coated balloon (DCB) (Philips) showed “excellent” safety and effectiveness in a real-world population of patients with complex peripheral artery disease (PAD).

The Stellarex drug-coated...

01/23/2020

Vascular Disease Management

Paclitaxel Comes Up Clean in Multiple Real-World Datasets

01/23/2020

Findings from 7 different real-world data sources show no difference in survival following treatment with drug-coated and non-drug-coated devices, according to a presentation given today at the International Symposium on Endovascular Therapy...

Findings from 7 different...

01/23/2020

Vascular Disease Management

Lutonix Safety Data Shows No Increase in Death with DCB vs PTA

01/23/2020

Hollywood, FL (January 23, 2020) – In a pooled analysis that included more than 1000 patients treated with the Lutonix 035 drug-coated balloon (DCB) (BD), no increase in mortality risk was seen compared to those treated with uncoated balloon...

Hollywood, FL (January 23, 2020)...

01/23/2020

Vascular Disease Management

Interview

Treating From Below: A Physician Perspective on Pedal Access and the Lutonix® 018 DCB

01/21/2020

This article first appeared in Cath Lab Digest, Volume 27 - Issue 11 - November 2019 Can you tell us about your lab and practice?

This article first appeared in...

01/21/2020

Vascular Disease Management

Interview

Improving Care of CLI and Complex PAD

01/21/2020

Vascular Disease Management spoke with Richard Neville, MD, Associate Director, INOVA Heart and Vascular Institute at INOVA Health System in Falls Church, Virginia. Dr. Neville discussed the importance of a multidisciplinary approach to...

Vascular Disease Management...

01/21/2020

Vascular Disease Management

Review

Renal Artery Fibromuscular Dysplasia

01/21/2020

Fibromuscular dysplasia (FMD) is a non-atherosclerotic, non-inflammatory arterial disease that primarily affects women.1 It most commonly affects the renal, extra-cranial carotid, and vertebral arteries, but has been reported in almost every...

Fibromuscular dysplasia (FMD) is...

01/21/2020

Vascular Disease Management